| Filed On | Filing |
|---|---|
| 06 Aug 2026 |
8-K: Other Events
This opinion is furnished to you in connection with (i) the Registration Statement on Form S-3 (File No. 333-287325) (the “Registration Statement”) filed by Solid Biosciences Inc., a Delaware corporation (the “Company”), with the Securit... |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Solid Biosciences Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 10, 2026 to consider and vote upon the matters listed below. The following is a summary of the matters voted on at the Annual M... |
| 10 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
For the sole purpose of achieving an equal balance of membership among the three classes of the Board of Directors (the “Board”) of Solid Biosciences Inc. (the “Company”), effective at 4:00 p.m., Eastern Time, on April 10, 2026, Ilan Gan... |
| 12 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
On March 11, 2026, Solid Biosciences Inc. (the “Company”) made available an updated corporate presentation on its website. |
| 06 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 6, 2026 by and among Solid Biosciences Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (ea... |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions |
| 13 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
At the Annual Meeting of Stockholders of Solid Biosciences Inc. (the “Company”) held on June 12, 2025 (the “Annual Meeting”), the Company’s stockholders approved an amendment to the Company’s Amended and Restated 2020 Equity Incentive Pl... |
| 15 May 2025 |
8-K: Other Events
Re: Prospectus Supplement to Registration Statement on Form S-3 |
| 18 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Pre-Funded Warrants to Purchase 13,888,340 Shares of Common Stock |
| 18 Feb 2025 |
8-K: Other Events
On February 18, 2025, Solid Biosciences Inc. (the “Company”) issued a press release announcing the pricing of a $200.0 million underwritten offering, which is expected to close on February 19, 2025. |
| 18 Feb 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Exhibit 99.1 February 2025 SGT-003 INSPIRE DUCHENNE DATA UPDATE © 2025 Solid Biosciences |
| 11 Jun 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 08 Jan 2024 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 8, 2024 by and among Solid Biosciences Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (... |
| 15 Nov 2023 |
8-K: Regulation FD Disclosure; Other Events
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 |
| 09 Jun 2023 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 22 May 2023 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 20 Mar 2023 |
8-K: Regulation FD Disclosure
Exhibit 99.1 SOLID BIO SCIENCES IGNITE DMD Phase I/II Study of SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy Roxana Donisa Dreghici1, J. Patrick Gonzalez1, Kristy J. Brown1, Carl A. Morris1, Perry Shieh2, Barry Byr... |
| 13 Mar 2023 |
8-K: Regulation FD Disclosure
Solid Biosciences Inc. (the “Company”) currently maintains a de minimis amount of cash, less than $1.0 million, in checking accounts at Silicon Valley Bank (“SVB”). The balance of the Company’s capital resources are held in custodial acc... |
| 09 Jan 2023 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +2 more
Solid Biosciences 41st Annual J.P. Morgan Healthcare Conference JANUARY 12, 2023 Exhibit 99.1 |
| 05 Dec 2022 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
To the Stockholders and the Board of Directors of AavantiBio, Inc. |
Loading...